JPRN-jRCT2061220045招募中1 期
Phase I study of RO7187797 in patients with Multiple myeloma.
anki Toshihiro0 个研究点目标入组 6 人开始时间: 2022年7月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Eastern Cooperative Oncology Group(ECOG)Performance Status (PS) is 0 or 1.
- •Survival of at least 12 weeks after the date of enrollment was judged to be possible.
- •Relapsed/refractory multiple myeloma for which standard therapy is ineffective and inappropriate.
排除标准
- •They have a history of the following immune-mediated side effects of previous immunotherapy:
- •Adverse events Grade 3 or more observed with treatment with anti PD-L1, anti PD-1, or anti CTLA4 therapeutic Abs. Except for Grade 3 endocrine disorders that can be managed with alternative therapies
- •Allogeneic stem cell transplantation was performed in the past.
- •Plasma cell count in peripheral blood exceeds 500/micro liter or plasma cell ratio in differential white blood cell count exceeds 5%.
研究者
相似试验
进行中（未招募）
1 期
A phase II study of CP-751,871 in patients with recurrent and/or metastatic squamous head and neck carcinoma - IGF-1R protocolEUCTR2008-004707-59-FRCliniques Universitaires Saint Luc-Centre du Cancer
进行中（未招募）
不适用
A phase II study of CP-751,871 in patients with recurrent and/or metastatic squamous head and neck carcinoma - IGF-1R protocolEUCTR2008-004707-59-BECliniques Universitaires Saint Luc-Centre du Cancer37
未知
2 期
A M117101 phase II study in patients with primary palmar hyperhidrosisprimary palmar hyperhidrosisJPRN-jRCT2080222374Maruho Co.,Ltd.
未知
1 期
Phase 1 study of ONO-7056Solid tumorJPRN-jRCT2080221709ONO PHARMACEUTICAL CO.,LTD.36
未知
1 期
Phase I study of ONO-7268MX1Hepatocellular carcinomaJPRN-jRCT2080221888ONO PHARMACEUTICAL CO.,LTD.18